Futura’s AGM statement demonstrates continued progress. A regulatory filing of an extended shelf life version of the CSD500 erectogenic condom is planned for later this year, and the clinical trial of topical erectile dysfunction product MED2002 is at an advanced stage of preparation. Most importantly at this stage, the clinical trial of the company’s topical pain relief portfolio is on track to deliver headline data by mid-July. We retain a positive stance.